109 related articles for article (PubMed ID: 15548851)
1. Effect of water intake on pharmacokinetics of lansoprazole from fast disintegrating tablet in human subjects.
Iwasaki K; Ito Y; Shibata N; Takada K; Sakurai Y; Takagi N; Irie S; Nakamura K
Drug Metab Pharmacokinet; 2004 Oct; 19(5):390-5. PubMed ID: 15548851
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of fast disintegrating lansoprazole tablet in human subjects.
Iwasaki K; Yoshikawa Y; Shibata N; Takada K; Sakurai Y; Takagi N; Irie S; Nakamura K
Drug Metab Pharmacokinet; 2004 Jun; 19(3):227-35. PubMed ID: 15499190
[TBL] [Abstract][Full Text] [Related]
3. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor.
Baldi F; Malfertheiner P
Digestion; 2003; 67(1-2):1-5. PubMed ID: 12743433
[TBL] [Abstract][Full Text] [Related]
5. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
Freston JW; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
Freston JW; Chiu YL; Mulford DJ; Ballard ED
Aliment Pharmacol Ther; 2003 Feb; 17(3):361-7. PubMed ID: 12562448
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
Cho HY; Yoon H; Park GK; Lee YB
Clin Ther; 2009 Nov; 31(11):2712-21. PubMed ID: 20110013
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
Amer F; Karol MD; Pan WJ; Griffin JS; Lukasik NL; Locke CS; Chiu YL
Clin Ther; 2004 Dec; 26(12):2076-83. PubMed ID: 15823771
[TBL] [Abstract][Full Text] [Related]
9. Formulation study for lansoprazole fast-disintegrating tablet. III. Design of rapidly disintegrating tablets.
Shimizu T; Sugaya M; Nakano Y; Izutsu D; Mizukami Y; Okochi K; Tabata T; Hamaguchi N; Igari Y
Chem Pharm Bull (Tokyo); 2003 Oct; 51(10):1121-7. PubMed ID: 14519914
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and absolute bioavailability of lansoprazole.
Gerloff J; Mignot A; Barth H; Heintze K
Eur J Clin Pharmacol; 1996; 50(4):293-7. PubMed ID: 8803522
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
12. Formulation study for lansoprazole fast-disintegrating tablet. I. Effect of compression on dissolution behavior.
Shimizu T; Nakano Y; Morimoto S; Tabata T; Hamaguchi N; Igari Y
Chem Pharm Bull (Tokyo); 2003 Aug; 51(8):942-7. PubMed ID: 12913232
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers.
Barclay ML; Begg EJ; Robson RA; Peters WA; Ketelbey JW
Aliment Pharmacol Ther; 1999 Sep; 13(9):1215-9. PubMed ID: 10468704
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation.
Chun AH; Erdman K; Chiu YL; Pilmer BL; Achari R; Cavanaugh JH
Clin Ther; 2002 Aug; 24(8):1322-31. PubMed ID: 12240782
[TBL] [Abstract][Full Text] [Related]
15. Formulation study for lansoprazole fast-disintegrating tablet. II. Effect of triethyl citrate on the quality of the products.
Shimizu T; Kameoka N; Iki H; Tabata T; Hamaguchi N; Igari Y
Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1029-35. PubMed ID: 12951443
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration.
Mainz D; Borner K; Koeppe P; Kotwas J; Lode H
J Antimicrob Chemother; 2002 Nov; 50(5):699-706. PubMed ID: 12407126
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
[TBL] [Abstract][Full Text] [Related]
18. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects.
Zhang D; Yang M; Liu M; Zhang Y; Wang X; Xiao X; Liu H
Xenobiotica; 2012 Nov; 42(11):1156-62. PubMed ID: 22612620
[TBL] [Abstract][Full Text] [Related]
20. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
